WST Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
872.3M
+3.2%
844.9M
+5.0%
805.0M
+0.0%
804.6M
+5.0%
766.5M
Cost of Revenue
543.1M
-1.0%
548.5M
+9.5%
501.1M
-1.8%
510.3M
+3.6%
492.6M
Gross Profit
329.2M
+11.1%
296.4M
-2.5%
303.9M
+3.3%
294.3M
+7.4%
273.9M
Operating Expenses
137.3M
+19.1%
115.3M
-10.5%
128.8M
+7.5%
119.8M
+4.2%
115.0M
R&D
19.7M
+24.7%
15.8M
-27.5%
21.8M
+27.5%
17.1M
-10.5%
19.1M
SG&A
117.6M
+18.2%
99.5M
-7.0%
107.0M
+4.2%
102.7M
+7.1%
95.9M
Operating Income
191.9M
+6.0%
181.1M
+3.4%
175.1M
+0.3%
174.5M
+9.8%
158.9M
EBITDA
238.1M
+5.2%
226.3M
+1.9%
222.1M
+2.1%
217.5M
+8.6%
200.3M
Net Income
154.0M
+11.0%
138.8M
+5.1%
132.1M
-5.6%
140.0M
+6.2%
131.8M
EPS (Basic)
$2.17
+12.4%
$1.93
+5.5%
$1.83
-5.7%
$1.94
+6.6%
$1.82
EPS (Diluted)
$2.15
+12.0%
$1.92
+5.5%
$1.82
-5.2%
$1.92
+5.5%
$1.82
Shares (Diluted)
71.3M
-1.5%
72.4M
-0.4%
72.7M
+0.1%
72.6M
+0.1%
72.5M
West Pharmaceutical Services (WST) โ€” Financials